<PAGE>

                       SECURITIES AND EXCHANGE COMMISSION

                             Washington, D.C. 20549

                                    FORM 10-Q

 /x/ QUARTERLY REPORT PURSUANT TO SECTION 13 or 15(d) OF THE
     SECURITIES EXCHANGE ACT OF 1934

For Quarter Ended September 30, 2000
                                       OR

/ / TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
     SECURITIES EXCHANGE ACT OF 1934

For the transition period from                     to
                                -----------------      ------------------


                          Commission File Number 0-6516

                                DATASCOPE CORP.
-------------------------------------------------------------------------------
             (Exact name of registrant as specified in its charter)

Delaware                                          13-2529596
-------------------------------------------------------------------------------
(State of other jurisdiction of                   (I.R.S. Employer
incorporation or organization)                    Identification No.)

                      14 Philips Parkway, Montvale, New Jersey  07645-9998
-------------------------------------------------------------------------------
                            (Address of principal executive offices)

                                 (201) 391-8100
-------------------------------------------------------------------------------
              (Registrant's telephone number, including area code)

Former name, former address and former fiscal year, if changed since last
report:

     Indicate by check mark whether the registrant
     (1) has filed all reports required to be filed by Section 13 or 15 (d) of
         the Securities Exchange Act of 1934 during the preceding 12 months (or
         for such shorter period that the registrant was required to file such
         reports), and

     (2) has been subject to such filing requirements for the past 90 days.
                YES   X             No
                     ---               ---

Number of Shares of Company's Common Stock outstanding as of
October 31, 2000:    14,811,646.


<PAGE>


                        Datascope Corp. and Subsidiaries
                     Management's Discussion and Analysis of
                  Results of Operations and Financial Condition

Results of Operations

         First quarter of fiscal 2001 compared to the corresponding period last
year.

     Net Sales

         Net sales of $67.8 million in the first quarter of fiscal 2001
         increased $4.3 million or 7% from $63.5 million last year.

         Sales of the Cardiac Assist / Monitoring Products segment increased
         $3.0 million or 6% to $49.8 million from $46.8 million.

              Sales of Cardiac Assist products increased 4% to $26.3 million,
              due to increased balloon pump sales, generated by the continued
              market penetration of the System 98. The Profile 8 Fr. catheter
              continues to be a significant factor in IAB sales and now
              represents approximately 60% of total balloon catheter sales.

              Patient Monitoring sales increased 9% to $23.6 million. Sales of
              Passport(R) products increased substantially due to the strong
              customer demand for the new Passport 2, the company's next
              generation portable, battery powered bedside monitor. The Passport
              2 was introduced in international markets in the second quarter of
              fiscal 2000 and in the U.S. market in the third quarter of fiscal
              2000. Additionally, the Accutorr(R) Plus blood pressure monitor
              and Masimo SpO2 sensors continued to experience strong customer
              demand.

         Sales of the Collagen Products / Vascular Grafts segment increased $1.3
         million or 8% to $18.0 million from $16.7 million.

              Sales of VasoSeal(R) arterial puncture sealing devices increased
              9% to $13 million. Sales growth compared to last fiscal year was
              lower as competitive sales resources and competitive product
              evaluations increased. At the same time, VasoSeal's sales
              resources were significantly below normal strength because of open
              sales territories. During the quarter, the company recruited new
              sales representatives and clinical specialists needed to fill all
              open territories. In addition, the company is currently completing
              a 20% expansion of its field sales organization, in order to meet
              the challenge of increased competition. The company anticipates
              that its replenished and expanded complement of field resources
              will begin to become effective when training is completed in the
              third quarter.


<PAGE>



              InterVascular's sales rose 6%, excluding the impact of foreign
              exchange rates, due to continued strong demand for the
              InterGard(R) Silver, the world's first anti-microbial vascular
              graft, primarily in European markets. Sales to the U.S. market
              increased 38%, reversing the decline experienced in the previous
              three quarters, when our U.S. distributor reduced inventory. After
              foreign exchange adjustment, InterVascular sales declined modestly
              to $4.5 million.

         The stronger U.S. dollar compared to major European currencies
         decreased total sales by approximately $1.1 million in the first
         quarter of fiscal 2001.

     Gross Profit (Net Sales Less Cost of Sales)

         The gross profit percentage was 60.1% for the first quarter compared to
         61.9% for the same period last year. The gross profit percentage in the
         first quarter of fiscal 2001 was impacted by lower average selling
         prices for certain patient monitoring products and a less favorable
         sales mix.

     Research and Development (R&D)

         R&D expenses, as a percentage of sales, were 9.2% for the first quarter
         of fiscal 2001, compared to 10.2% for the corresponding period last
         year.

         R&D expenses were $6.3 million in the first quarter of fiscal 2001
         compared to $6.5 million last year. The 4% decrease was primarily due
         to reduced development expenses in the Patient Monitoring product line.

     Selling, General & Administrative Expenses (SG&A)

         SG&A expenses, as a percentage of sales, were 39.9% in the first
         quarter of fiscal 2001, compared to 41.9% last year.

         SG&A expenses of $27.0 million in the first quarter of fiscal 2001
         increased $0.4 million or 2% primarily as a result of higher selling
         and marketing expenses in the VasoSeal and Cardiac Assist product lines
         related to new marketing programs and the higher sales.

         The stronger U.S. dollar compared to major European currencies
         decreased SG&A expenses by approximately $0.7 million in the first
         quarter of fiscal 2001.

     Interest Income and Expense

         Interest income in the fiscal 2001 first quarter of $1.1 million,
         increased $0.2 million or 27% compared to the first quarter last year.
         The higher interest income was attributable to a 6% increase in the
         average investment portfolio from $67.8 million to $71.9 million and an
         increase in the average yield to 6.1% from 5.1%.


<PAGE>



         During the first quarter, the company recorded a pretax gain of $593
         thousand, or $0.02 per share after tax, from the sale of an
         underutilized facility in Oakland, New Jersey.

     Income Taxes

         The consolidated effective tax rate was 32.0% for the first quarter of
         fiscal 2001 compared to 31.0% last year. The higher tax rate was due
         mainly to the impact of higher earnings taxed at a higher statutory tax
         rate and expiration of a tax exemption for a manufacturing subsidiary
         in Europe.

     Net Earnings

         Net earnings were $6.1 million or $0.39 per diluted share in the first
         quarter of fiscal 2001 compared to $4.8 million, or $0.30 per diluted
         share last year.

         The increased earnings reflect:
             o   higher gross margin from increased sales
             o   greater expense control
             o   non-recurring gain of $593 thousand or $0.02 per diluted share
                 after tax related to the sale of an underutilized facility
             o   increased interest income of $231 thousand described above.

Liquidity and Capital Resources

     Working capital was $121.4 million at September 30, 2000, compared to
     $120.8 million at June 30, 2000 and the current ratio was 3.4:1 compared to
     3.3:1. The modest increase in working capital and current ratio were
     primarily due to a decline in accrued compensation expenses.

     In the first three months of fiscal 2001 cash provided by operations was
     $9.7 million, compared to $8.1 million last year. The $1.6 million increase
     primarily reflects higher net earnings and lower inventories. Net cash used
     in investing activities was $3.0 million, attributable to the purchase of
     $3.0 million of property, plant and equipment. Net cash used in financing
     activities was $6.4 million, primarily due to stock repurchases of $5.5
     million and $0.6 million dividends paid.

     Through September 30, 2000 we expended $5.5 million to purchase about
     160,000 shares of our common stock under the current $30 million stock
     repurchase program.

     On August 18, 2000, the Board of Directors declared a quarterly cash
     dividend of $0.04 per share payable on September 29, 2000 to stockholders
     of record at September 1, 2000.

     We believe our financial resources are sufficient to meet our projected
     cash requirements.

     The moderate rate of current U.S. inflation has not significantly affected
     the company.




<PAGE>



Euro Conversion

     As part of the European Economic and Monetary Union (EMU), a single
     currency (Euro) will replace the national currencies of most of the
     European countries in which we conduct our business. The conversion rates
     between the Euro and the participating nations' currencies have been fixed
     irrevocably as of January 1, 1999. During a transition period from January
     1, 1999 to December 31, 2001 parties may settle transactions using either
     Euro or the participating country's national currency. The participating
     national currencies will be removed from circulation between January 1,
     2002 and June 30, 2002 and replaced by Euro notes and coinage. Full
     conversion of all affected country operations to the Euro currency is
     expected to be completed by the time national currencies are removed from
     circulation.

     We are currently involved in the phased conversion to the Euro and the
     effects on revenues, costs and various business strategies are being
     assessed. We are able to conduct business in both the Euro and national
     currencies on an as needed basis, as required by the European Union. The
     cost of software and business process conversion is not expected to be
     material to our financial condition or results of operations.

Information Concerning Forward Looking Statements

     This Management's Discussion and Analysis of Results of Operations and
     Financial Condition includes forward-looking statements that involve risks
     and uncertainties because of the possibility that market conditions may
     change, particularly as the result of competitive activity in the cardiac
     assist, arterial sealing and other markets served by the company, the
     company's ability to gain market acceptance for new products and the
     company's dependence on certain suppliers for patient monitoring and
     VasoSeal products. Additional risks are the ability of the company to
     successfully introduce new products, continued demand for the company's
     products generally, the rapid and significant changes that characterize the
     medical device industry and the ability to continue to respond to such
     technological changes, the uncertain timing of regulatory approvals, as
     well as other risks detailed from time to time in documents filed by
     Datascope with the Securities and Exchange Commission.

Quantitative and Qualitative Disclosures About Market Risk

     Due to the global nature of our operations, we are subject to the exposures
     that arise from foreign exchange rate fluctuations. Our objective in
     managing the exposure to foreign currency fluctuations is to minimize net
     earnings volatility associated with foreign exchange rate changes. We enter
     into foreign currency forward exchange contracts to hedge a substantial
     portion of the foreign currency transactions which are primarily related to
     certain intercompany receivables denominated in foreign currencies. Our
     hedging activities do not subject us to exchange rate risk because gains
     and losses on these contracts offset losses and gains on the assets,
     liabilities and transactions being hedged.


<PAGE>



     We do not use derivative financial instruments for trading purposes. None
     of our foreign currency forward exchange contracts are designated as
     economic hedges of our net investment in foreign subsidiaries.

     As of September 30, 2000, we had a notional amount of $4.3 million of
     foreign exchange forward contracts outstanding, all of which were in
     European currencies. The foreign exchange forward contracts generally have
     maturities that do not exceed 12 months and require us to exchange foreign
     currencies for U.S. dollars at maturity, at rates agreed to when the
     contract is signed.

     Statement of Financial Accounting Standards No. 133, "Accounting for
     Derivative Instruments and Hedging Activities"(SFAS No. 133), establishes
     accounting and reporting standards for derivative instruments and for
     hedging activities. It requires companies to recognize all derivatives as
     either assets or liabilities in the statement of financial position and
     measure those instruments at fair value. We have adopted SFAS No. 133 in
     the first quarter of fiscal 2001, in accordance with the deferral provision
     in SFAS No. 137. The adoption of SFAS No. 133 did not have a material
     effect on our financial statements.

<PAGE>

                        Datascope Corp. and Subsidiaries
                           Consolidated Balance Sheets
                                 (In thousands)

<TABLE>
<CAPTION>
                                                                        Sept 30,          June 30,
                                                                          2000              2000
                                                                     ---------------      ---------------
Assets                                                                (unaudited)                (a)
Current Assets:
<S>                                                                  <C>                   <C>
  Cash and cash equivalents                                          $        2,643        $       2,102
  Short-term investments                                                     57,118               53,096
  Accounts receivable less allowance for
    doubtful accounts of $1,635 and $1,644                                   61,945               69,081
  Inventories                                                                39,610               38,986
  Prepaid expenses and other current assets                                  11,236               10,014
                                                                     ---------------      ---------------
      Total Current Assets                                                  172,552              173,279

Property, Plant and Equipment, net of accumulated
    depreciation of $59,483 and $58,234                                      86,855               86,243
Non-Current Marketable Securities                                             8,138               12,235
Other Assets                                                                 23,941               23,034
                                                                     ---------------      ---------------
                                                                      $     291,486        $     294,791
                                                                     ===============      ===============

Liabilities and Stockholders' Equity
Current Liabilities:
  Accounts payable                                                   $       14,668        $      14,250
  Accrued expenses                                                           13,262               11,165
  Accrued compensation                                                       14,727               19,662
  Deferred revenue                                                            4,216                4,773
  Taxes on income                                                             4,273                2,630
                                                                     ---------------      ---------------
      Total Current Liabilities                                              51,146               52,480

Other Liabilities                                                            14,462               14,524
Stockholders' Equity
  Preferred stock, par value $1.00 per share:
    Authorized 5 million shares; Issued, none                                    --                   --
  Common stock, par value $.01 per share:
    Authorized, 45 million shares; Issued and
    outstanding, 17,098 and 17,028 shares                                       171                  170
  Additional paid-in capital                                                 60,357               60,646
  Treasury stock at cost, 2,309 and 2,149 shares                            (60,714)             (55,247)
  Retained earnings                                                         235,675              230,187
  Accumulated other comprehensive loss                                       (9,611)              (7,969)
                                                                     ---------------      ---------------
                                                                            225,878              227,787
                                                                     ---------------      ---------------
                                                                      $     291,486        $     294,791
                                                                     ===============      ===============
</TABLE>


                  (a) Derived from audited financial statements
                 See notes to consolidated financial statements


<PAGE>

                        Datascope Corp. and Subsidiaries
                       Statements of Consolidated Earnings
                    (In thousands, except per share amounts)
                                   (Unaudited)

<TABLE>
<CAPTION>
                                                                  Three Months Ended
                                                                    September 30,
                                                          -----------------------------------
                                                              2000              1999
                                                          --------------       --------------

<S>                                                       <C>                  <C>
Net Sales                                                 $      67,800         $     63,500
                                                          --------------       --------------

Costs and Expenses:
  Cost of sales                                                  27,072               24,214
  Research and development
    expenses                                                      6,256                6,497
  Selling, general and
    administrative expenses                                      27,030               26,606
                                                          --------------       --------------
                                                                 60,358               57,317
                                                          --------------       --------------

Operating Earnings                                                7,442                6,183

Other (Income) Expense:
  Interest income                                                (1,098)                (867)
  Interest expense                                                    2                    2
  Other, net                                                       (408)                  48
                                                          --------------       --------------
                                                                 (1,504)                (817)
                                                          --------------       --------------

Earnings Before Taxes on Income                                   8,946                7,000

Taxes on Income                                                   2,863                2,170
                                                          --------------       --------------

Net Earnings                                              $       6,083          $     4,830
                                                          ==============       ==============


Earnings Per Share, Basic                                 $        0.41          $      0.32
                                                          ==============       ==============
Weighted average common
   shares outstanding, Basic                                     14,858               15,206
                                                          ==============       ==============

Earnings Per Share, Diluted                                 $      0.39          $      0.30
                                                          ==============       ==============
Weighted average common
   shares outstanding, Diluted                                   15,595               16,093
                                                          ==============       ==============
</TABLE>



                 See notes to consolidated financial statements



<PAGE>

                        Datascope Corp. and Subsidiaries
                      Statements of Consolidated Cash Flows
                             (Dollars in thousands)
                                   (Unaudited)

<TABLE>
<CAPTION>
                                                                                   Three Months Ended
                                                                                     September 30,
                                                                            ---------------------------------
                                                                                  2000               1999
                                                                            --------------     --------------
<S>                                                                          <C>                <C>
Operating Activities:
   Net cash provided by operating activities                                 $      9,732       $      8,103
                                                                            --------------     --------------

Investing Activities:
   Capital expenditures                                                            (3,043)            (3,282)
   Purchases of marketable securities                                              (7,961)           (14,499)
   Maturities of marketable securities                                              8,036             17,003
                                                                            --------------     --------------
   Net cash used in investing activities                                           (2,968)              (778)
                                                                            --------------     --------------

Financing Activities:
   Treasury shares acquired under repurchase programs                              (5,467)           (10,348)
   Exercise of stock options                                                         (288)             1,028
   Cash dividends paid                                                               (595)                 0
                                                                            --------------     --------------
   Net cash used in financing activities                                           (6,350)            (9,320)
                                                                            --------------     --------------
   Effect of exchange rates on cash                                                   127                (95)
                                                                            --------------     --------------
Increase (decrease) in cash and cash equivalents                                      541             (2,090)
Cash and cash equivalents, beginning of period                                      2,102              4,572
                                                                            --------------     --------------
Cash and cash equivalents, end of period                                     $      2,643       $      2,482
                                                                            ==============     ==============
Supplemental Cash Flow Information
   Cash Paid during the period for:
     Income taxes                                                            $      1,223       $        726
                                                                            --------------     --------------

   Non-cash transactions:
      Net transfers of inventory to fixed assets
        for use as demonstration equipment                                   $      1,333       $      2,171
                                                                            --------------     --------------

</TABLE>


                 See notes to consolidated financial statements



<PAGE>

                        Datascope Corp. and Subsidiaries
                   Notes to Consolidated Financial Statements
                 (Unaudited, in thousands except per share data)

1.  Basis of Presentation

The consolidated financial statements include the accounts of Datascope Corp.
and its subsidiaries (the "Company" - which may be referred to as "our", "us" or
"we").

The consolidated balance sheet as of September 30, 2000 and the statements of
consolidated earnings and cash flows for the three month periods ended September
30, 2000 and 1999 have been prepared by the Company, without audit. In our
opinion, all adjustments (which include only normal recurring adjustments) have
been made that are necessary to present fairly the financial position, results
of operations and cash flows for all periods presented.

Certain information and footnote disclosures normally included in financial
statements prepared in accordance with generally accepted accounting principles
have been condensed or omitted. We suggest that you read these condensed
consolidated financial statements in conjunction with the financial statements
and notes included in our Annual Report on Form 10-K for the fiscal year ended
June 30, 2000. The results of operations for the period ended September 30, 2000
are not necessarily indicative of a full year's operations.

We have reclassified certain prior year information to conform with the current
year presentation.

2.  Inventories

Inventories are stated at the lower of cost or market, with cost determined on a
first-in, first-out basis.

                                              ---------------------------------
                                                Sept 30,             June 30,
                                                  2000                2000
                                              ------------         ------------
               Materials                          $18,232              $17,462
               Work in Process                      8,591                7,888
               Finished Goods                      12,787               13,636
                                              ------------         ------------
                                                  $39,610              $38,986
                                              ============         ============

3.  Stockholders' Equity

Changes in the components of stockholders' equity for the three months ended
September 30, 2000 were as follows:

               Net earnings                                      $6,083
               Foreign currency translation adjustments          (1,642)
               Common stock and additional paid-in
               capital effects of stock option activity            (288)
               Cash dividends on common stock                      (595)
               Purchases under stock repurchase plans            (5,467)
                                                               ---------
               Total decrease in stockholders' equity           ($1,909)
                                                               =========



<PAGE>

                        Datascope Corp. and Subsidiaries
                   Notes to Consolidated Financial Statements
                 (Unaudited, in thousands except per share data)

4.  Earnings Per Share

In accordance with Financial Accounting Standard No. 128, "Earnings Per Share",
we disclose both Basic and Diluted Earnings Per Share. The reconciliation of
Basic Earnings Per Share to Diluted Earnings Per Share is as follows:


<TABLE>
<CAPTION>
----------------------------    ----------------------------------      -----------------------------------
For Three Months Ended                  September 30, 2000                      September 30, 1999
----------------------------    ----------------------------------      -----------------------------------
                                    Net                  Per Share           Net                 Per Share
Basic EPS                        Earnings      Shares      Amount         Earnings    Shares       Amount
---------                       ----------  ----------- -----------     ----------- -----------  ----------
<S>                             <C>         <C>         <C>              <C>         <C>          <C>
Earnings available to
   common shareholders             $6,083       14,858       $0.41          $4,830      15,206       $0.32

Diluted EPS
Options issued to employees            --          737       (0.02)             --         887       (0.02)
                                ----------  ----------- -----------     ----------- -----------  ----------

Earnings available to
   common shareholders
   plus assumed conversions        $6,083       15,595       $0.39          $4,830      16,093       $0.30
                                ==========  =========== ===========     =========== ===========  ==========
</TABLE>


5.  Comprehensive Income

In accordance with Financial Accounting Standard No. 130, "Reporting
Comprehensive Income", we disclose comprehensive income and its components. For
the three month periods ended September 30, 2000 and 1999 our comprehensive
income was as follows:

                                                 -----------     -----------
                                                    2000            1999
                                                 -----------     -----------
         Net earnings                                $6,083          $4,830
         Foreign currency translation
           gain or (loss)                            (1,642)            692
                                                 -----------     -----------
         Total comprehensive income                  $4,441          $5,522
                                                 ===========     ===========


<PAGE>

                        Datascope Corp. and Subsidiaries
                   Notes to Consolidated Financial Statements
                 (Unaudited, in thousands except per share data)

6.  Segment Information

Our business is the development, manufacture and sale of medical devices. We
have two reportable segments, Cardiac Assist / Monitoring Products and Collagen
Products / Vascular Grafts.

The Cardiac Assist / Monitoring Products segment includes electronic
intra-aortic balloon pumps and catheters that are used in the treatment of
vascular disease and electronic physiological monitors that provide for patient
safety and management of patient care.

The Collagen Products / Vascular Grafts segment includes extravascular
hemostasis devices which are used to seal arterial puncture wounds to stop
bleeding after cardiovascular catheterization procedures and a proprietary line
of knitted and woven vascular grafts and patches for reconstructive vascular and
cardiovascular surgery.

We have aggregated our product lines into two segments based on similar
manufacturing processes, distribution channels, regulatory environments and
customers. Management evaluates the revenue and profitability performance of
each of our product lines to make operating and strategic decisions. We have no
intersegment revenue. Net sales and operating earnings are shown below.

<TABLE>
<CAPTION>
                                                            Cardiac         Collagen
                                                           Assist /        Products /       Corporate
                                                          Monitoring        Vascular           and
                                                           Products          Grafts           Other        Consolidated
-----------------------------------------------------   ----------------  ---------------- --------------  ----------------
<S>                                                     <C>               <C>              <C>             <C>
Three months ended September 30, 2000
-----------------------------------------------------
Net sales to external customers                                 $49,819           $17,981             --           $67,800
                                                        -------------------------------------------------------------------
Operating earnings                                               $3,190            $3,430           $822            $7,442
                                                        -------------------------------------------------------------------

-----------------------------------------------------
Three months ended September 30, 1999
-----------------------------------------------------
Net sales to external customers                                 $46,818           $16,682             --           $63,500
                                                        -------------------------------------------------------------------
Operating earnings                                               $3,250            $3,391          ($458)           $6,183
                                                        -------------------------------------------------------------------

Reconciliation to consolidated

earnings before income taxes:                                      2000              1999
-------------------------------
                                                        ----------------  ----------------
Consolidated operating earnings                                  $7,442            $6,183
Interest income, net                                              1,096               865
Other (expense) income                                              408               (48)
                                                        ----------------  ----------------
Consolidated earnings before taxes                               $8,946            $7,000
                                                        ================  ================
</TABLE>

<PAGE>

                        Datascope Corp. and Subsidiaries
                   Notes to Consolidated Financial Statements
                 (Unaudited, in thousands except per share data)

7.  Restructuring Program

Based upon a review by senior management of all company operations, a
restructuring plan was approved in fiscal year 1999 to reduce the company's cost
structure and streamline certain operations. We recorded pretax restructuring
charges totaling $3.43 million, or $0.14 per share, during the second half of
fiscal 1999 related to the following cost reduction initiatives:

   o     Closure of InterVascular's Clearwater, Florida leased manufacturing
         facility in order to reduce costs and centralize operations in our
         expanded manufacturing facility in LaCiotat, France.

   o     Workforce reductions in certain administrative, R&D and manufacturing
         positions throughout the company.

   o     Writedown of certain Genisphere fixed assets based on the revised
         market entry strategy for the proprietary 3DNA technology. Under the
         revised market entry stategy we will focus product development on
         improving the performance of newly-developing technologies for drug
         discovery used by the pharmaceutical and biotech industries.

A summary of the restructuring charges and remaining liability at September 30,
2000 is shown below.

<TABLE>
<CAPTION>
                                                           Clearwater                      Genisphere
                                                              Plant         Employee          Asset
                                                             Closure        Severance       Writedown         Total
                                                          --------------  --------------  -------------- ---------------
<S>    <C>                                                <C>             <C>             <C>            <C>
Fiscal 1999 restructuring charges                                 $880          $1,674            $875          $3,429
Utilized through fiscal 2000                                       722           1,363             875           2,960
Utilized in Q1 fiscal 2001                                          49              25              --              74
                                                          --------------  --------------  -------------- ---------------
Remaining liability at September 30, 2000                         $109            $286              --            $395
                                                          ==============  ==============  ============== ===============
</TABLE>

No additional expenditures are expected to complete the restructuring program.


<PAGE>



Part II:

    Item 6.   Exhibits and Reports on Form 8-K

              a.  Exhibits

                  none

              b.  Reports on Form 8-K. No reports on Form 8-K have been filed
                  during the quarter for which this report is filed.


<PAGE>



                                                                     Form 10-Q

     SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this Report to be signed on its behalf by the
undersigned, thereunto duly authorized.

                              DATASCOPE CORP.
                              Registrant

                              By: \s\   Lawrence Saper
                                  ---------------------------------------
                                    Chairman of the Board and
                                    Chief Executive Officer

                              By: \s\   Leonard S. Goodman
                                  -----------------------------------
                                    Vice President, CFO and Treasurer

Dated:  November 14, 2000